Please try another search
For the fiscal year ended 31 March 2022, TAISHO PHARMACEUTICAL HOLDINGS Co Ltd revenues decreased 5% to Y268.2B. Net income decreased 1% to Y13.12B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Advertising Expense increase of 28% to Y31.9B (expense), Other Selling/General/Admin. Expense increase of 5% to Y55.06B (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Total Revenue | 83576 | 82295 | 73712 | 83151 |
Gross Profit | 46480 | 46915 | 41490 | 50027 |
Operating Income | 2657 | 7287 | -106 | 10918 |
Net Income | 2873 | 3087 | -1902 | 10022 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Total Assets | 1005463 | 1000111 | 941490 | 946836 |
Total Liabilities | 148168 | 143811 | 132148 | 131287 |
Total Equity | 857295 | 856300 | 809342 | 815549 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review